Bafna Pharmaceuticals Limited (BAFNAPH.NS)
INR 78.05
(-4.33%)
INR 78.05
(-4.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 107.53 Million INR | 27.51% |
| 2022 | 84.33 Million INR | 6.86% |
| 2021 | 78.92 Million INR | 49.3% |
| 2020 | 52.86 Million INR | 75.17% |
| 2019 | 30.17 Million INR | -86.87% |
| 2018 | 229.88 Million INR | -1.12% |
| 2017 | 232.49 Million INR | -40.4% |
| 2016 | 390.1 Million INR | 10.92% |
| 2015 | 351.71 Million INR | 202.14% |
| 2014 | 116.4 Million INR | -49.27% |
| 2013 | 229.46 Million INR | -8.93% |
| 2012 | 251.97 Million INR | -4.3% |
| 2011 | 263.3 Million INR | -48.42% |
| 2010 | 510.47 Million INR | 71.33% |
| 2009 | 297.94 Million INR | 24.65% |
| 2008 | 239.02 Million INR | -3.59% |
| 2007 | 247.92 Million INR | 44.89% |
| 2006 | 171.11 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 71.1 Million INR | 0.0% |
| 2023 FY | 107.53 Million INR | 27.51% |
| 2023 Q4 | 107.53 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 84.33 Million INR | 0.0% |
| 2022 FY | 84.33 Million INR | 6.86% |
| 2022 Q2 | 63.89 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 30.45 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 78.92 Million INR | 0.0% |
| 2021 FY | 78.92 Million INR | 49.3% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 35.46 Million INR | 0.0% |
| 2020 FY | 52.86 Million INR | 75.17% |
| 2020 Q4 | 52.86 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 30.17 Million INR | -86.87% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 234.71 Million INR | 0.0% |
| 2019 Q4 | 30.17 Million INR | 0.0% |
| 2018 FY | 229.88 Million INR | -1.12% |
| 2018 Q4 | 229.88 Million INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 232.49 Million INR | -40.4% |
| 2016 FY | 390.1 Million INR | 10.92% |
| 2015 FY | 351.71 Million INR | 202.14% |
| 2014 FY | 116.4 Million INR | -49.27% |
| 2013 FY | 229.46 Million INR | -8.93% |
| 2012 FY | 251.97 Million INR | -4.3% |
| 2012 Q2 | 491.39 Million INR | 0.0% |
| 2012 Q4 | 251.97 Million INR | 0.0% |
| 2011 FY | 263.3 Million INR | -48.42% |
| 2010 FY | 510.47 Million INR | 71.33% |
| 2009 FY | 297.94 Million INR | 24.65% |
| 2008 FY | 239.02 Million INR | -3.59% |
| 2007 FY | 247.92 Million INR | 44.89% |
| 2006 FY | 171.11 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 265.79 Million INR | 59.544% |
| Ind-Swift Limited | 10.09 Billion INR | 98.935% |
| Bajaj HealthCare Limited | 650.34 Million INR | 83.465% |
| Sakar Healthcare Limited | 549.55 Million INR | 80.433% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.496% |
| Innova Captab Limited | 2.1 Billion INR | 94.892% |
| Divi's Laboratories Limited | 20 Million INR | -437.66% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -286.306% |
| Morepen Laboratories Limited | 33.64 Million INR | -219.655% |
| Mankind Pharma Limited | 325.81 Million INR | 66.996% |
| Sequent Scientific Limited | 1.42 Billion INR | 92.465% |
| Wanbury Limited | 820 Million INR | 86.886% |
| Laurus Labs Limited | 7.98 Billion INR | 98.653% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 92.336% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 27.151% |
| Alembic Limited | 73.9 Million INR | -45.51% |
| Hikal Limited | 4.22 Billion INR | 97.457% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 82.899% |
| Neuland Laboratories Limited | 449.2 Million INR | 76.062% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 54.513% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 92.911% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Themis Medicare Limited | 267.74 Million INR | 59.837% |
| RPG Life Sciences Limited | -30.3 Million INR | 454.891% |
| Zydus Lifesciences Limited | 251 Million INR | 57.159% |
| Lupin Limited | 1.55 Billion INR | 93.075% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -669.845% |
| Wockhardt Limited | 8.91 Billion INR | 98.793% |
| Vaishali Pharma Limited | 35.98 Million INR | -198.841% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -26783.0% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -42.295% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.66% |
| FDC Limited | 2.46 Million INR | -4260.584% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 98.205% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 98.357% |
| Venus Remedies Limited | 386.8 Million INR | 72.2% |
| ZIM Laboratories Limited | 356 Million INR | 69.795% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 69.788% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -1068.826% |
| Shilpa Medicare Limited | 5.6 Billion INR | 98.08% |
| Albert David Limited | 6.01 Million INR | -1687.434% |
| Ajanta Pharma Limited | 235.2 Million INR | 54.281% |
| Hester Biosciences Limited | 1.81 Billion INR | 94.084% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 49.362% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | 90.844% |
| Gufic Biosciences Limited | 1.53 Billion INR | 93.016% |
| Windlas Biotech Limited | 20.18 Million INR | -432.864% |
| Procter & Gamble Health Limited | 68.8 Million INR | -56.297% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -233.497% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 19.476% |
| Granules India Limited | 689.71 Million INR | 84.409% |
| Aarti Drugs Limited | 2.75 Billion INR | 96.094% |
| Bal Pharma Limited | 363.82 Million INR | 70.444% |
| Alkem Laboratories Limited | 400 Million INR | 73.117% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -708.511% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Medicamen Biotech Limited | 12.55 Million INR | -756.487% |
| Unichem Laboratories Limited | 382.22 Million INR | 71.867% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Valiant Laboratories Limited | 750.89 Million INR | 85.68% |
| Orchid Pharma Limited | 1.2 Billion INR | 91.071% |
| Medico Remedies Limited | 8.67 Million INR | -1139.991% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 3.668% |
| Ipca Laboratories Limited | 5.8 Billion INR | 98.147% |
| Brooks Laboratories Limited | 3.56 Million INR | -2916.325% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 8921.329% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.98% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.33% |
| NATCO Pharma Limited | 53 Million INR | -102.891% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 94.14% |
| Strides Pharma Science Limited | 6.71 Billion INR | 98.399% |
| Indoco Remedies Limited | 3.51 Billion INR | 96.943% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -0.874% |